Download PDF
Arzneimittelforschung 2010; 60(12): 731-748
DOI: 10.1055/s-0031-1296349
Review
Editio Cantor Verlag Aulendorf (Germany)

Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives

Nuggehally R Srinivas
1   Suramus Biopharm, Integrated Drug Development, Bangalore, India
› Author Affiliations
Further Information

Publication History

Publication Date:
03 December 2011 (online)

    Permissions and Reprints

Abstract

In the evolving paradigm of drug development it is a reasonable strategy to avoid and/or anticipate potential risks in drug development for select drugs by performing in vitro and/or preclinical studies in appropriate animal models. The availability of acute renal failure (ARF) rat models provides an opportunity to explore the pharmacokinetic disposition of drugs and associated metabolites in conditions that mimic the pathophysiology of the disease in humans. Such studies may help in drug(s) selection for development, differentiating certain drug classes, and/or arriving at a dose strategy decision in the clinic.

Scores of compounds, belonging to various therapeutic areas, have undergone pharmacokinetic investigations in ARF models induced by uranyl nitrate (CAS 10102-06-4), glycerol (CAS 56-81-5), cisplatin (CAS 15663-27-1) or gentamicin (CAS 1403-66-3) in rats. The published pharmacokinetic disposition data has unequivocally suggested that ARF conditions leads to decreased renal elimination of the drug and associated metabolites; however, the influence on the overall body clearance is dependent on the propensity of the contribution of renal versus non-renal mechanisms of elimination. In the case studies assembled for this review, 52.5% of the drugs showed an increased drug exposure, 35% of the drugs showed a decreased drug exposure and 12.5% of the drugs showed no altered exposure, in ARF rat models relative to control rats. Interestingly, ARF can have an overall impact on drug absorption, distribution, metabolism, local transport and biliary excretion. Hence, the overall pharmacokinetic disposition may have to be interpreted with caution during ARF since there is the potential for competiting pathways to co-exist. For instance, due to reduced renal elimination as a result of kidney insult caused by ARF, compensatory biliary excretion mechanism may occur. Alternatively, intestinal and/or hepatic enzymatic expression level may go up to facilitate enhanced metabolism. However, there may be instances where uraemic toxins floating in the circulation may block the metabolism and/or may also retard the absorption process.

This review covers: 1) an illustration of a number of case studies providing tabulated information on the key altered pharmacokinetic parameters observed in ARF and the hypothesized mechanistic explanation; 2) a comprehensive description of altered absorption, distribution, metabolism, excretion and efflux transport related changes observed during ARF; 3) a general framework for drug development strategies and 4) a succinct discussion on the overall perspectives of the applicability of ARF rat models.

Key words

Acute renal failure - Case studies - Pharmacokinetic parameters - Rat models
 

  • Literature

  • 1 Heimbach T, Lakshminarayana SB, Hu W, He H. Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data. AAPS J. 2009; 11: 602-14
    CrossrefPubMedGoogle Scholar
  • 2 Hsieh Y, Cheng KC, Wang Y, Chackalamannil S, Xia Y, Korf-macher WA, White RE. The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development. Curr Pharm Des. 2009; 15: 2262-9
    CrossrefPubMedGoogle Scholar
  • 3 Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokin. 2009; 24: 16-24
    CrossrefPubMedGoogle Scholar
  • 4 Srinivas NR. Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?. Xenobio-tica. 2009; 39: 193-6
    CrossrefPubMedGoogle Scholar
  • 5 Brenner BM, Lazarus JM. Acute renal failure. 3rd ed New York (NY): Churchill Livingstone; 1992: 359-360
    Google Scholar
  • 6 Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8: R204-12
    CrossrefPubMedGoogle Scholar
  • 7 Lieberthal W, Nigam SK. Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. Am J Physiol. 1998; 275 (5 Pt 2) F623-31
    PubMedGoogle Scholar
  • 8 Elapavaluru S, Kellum JA. Why do patients die of acute kidney injury?. Acta Clin Belg. 2007; 2 (Suppl) 326-31
    PubMedGoogle Scholar
  • 9 Lieberthal W, Nigam SK. Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable. Am J Physiol Renal Physiol. 2000; 278: F1-12
    PubMedGoogle Scholar
  • 10 Nigam S, Lieberthal W. Acute renal failure. III. The role of growth factors in the process of renal regeneration and repair. Am J Physiol Renal Physiol. 2000; 279: F3-11
    PubMedGoogle Scholar
  • 11 Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven’t worked and what is on the horizon. Clin J Am Soc Nephrol. 2007; 2: 356-65
    CrossrefPubMedGoogle Scholar
  • 12 Goodsaid FM, Blank M, Dieterle F, Harlow P, Hausner E, Sistare F, Thompson A, Vonderscher J. Novel biomarkers of acute kidney toxicity. Clin Pharmacol Ther. 2009; 86: 490-6
    CrossrefPubMedGoogle Scholar
  • 13 Stojnev S, Pejcic M, Dolicanin Z, Velickovic LJ, Dimov I, Stefanovic V. Challenges of genomics and proteomics in nephrology. Ren Fail. 2009; 31: 765-72
    CrossrefPubMedGoogle Scholar
  • 14 Choi YH, Lee YS, Kim TK, Lee BY, Lee MG. Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2. J Pharm Pharmacol. 2009; 61: 1325-32
    CrossrefPubMedGoogle Scholar
  • 15 Izuwa Y, Kusaba J, Horiuchi M, Aiba T, Kawasaki H, Kurosaki Y. Comparative study of increased plasma quinidine concentration in rats with glycerol- and cisplatin-induced acute renal failure. Drug Metab Pharmacokinet. 2009; 24: 451-7
    CrossrefPubMedGoogle Scholar
  • 16 Sakae R, Ishikawa A, Niso T, Komori Y, Aiba T, Kawasaki H, Kurosaki Y. Decreased lithium disposition to cerebrospinal fluid in rats with glycerol-induced acute renal failure. Pharm Res. 2008; 25: 2243-9
    CrossrefPubMedGoogle Scholar
  • 17 Lee DY, Jung YS, Shin HS, Lee I, Kim YC, Lee MG. Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies. J Pharm Pharmacol. 2008; 60: 843-51
    CrossrefPubMedGoogle Scholar
  • 18 Shim WS, Park JH, Ahn SJ, Han L, Jin QR, Li H, Choi MK, Kim DD, Chung SJ, Shim CK. Testosterone-independent down-regulation of Oct2 in the kidney medulla from a uranyl nitrate-induced rat model of acute renal failure: effects on distribution of a model organic cation, tetraethylammonium. J Pharm Sci. 2009; 98: 739-47
    CrossrefPubMedGoogle Scholar
  • 19 Venkatesh P, Harisudhan T, Choudhury H, Mullangi R, Srinivas NR. Pharmacokinetics of etoposide in rats with uranyl nitrate (UN)-induced acute renal failure (ARF): optimization of the duration of UN dosing. Eur J Drug Metab Pharmacokinet. 2007; 32: 189-96
    CrossrefPubMedGoogle Scholar
  • 20 Lee JH, Lee MG. Effects of acute renal failure on the pharmacokinetics of telithromycin in rats: negligible effects of increase in CYP3A1 on the metabolism of telithromycin. Biopharm Drug Dispos. 2007; 28: 157-66
    CrossrefPubMedGoogle Scholar
  • 21 Tanabe H, Taira S, Taguchi M, Hashimoto Y. Pharmacokinetics and hepatic extraction of metoprolol in rats with glycerol-induced acute renal failure. Biol Pharm Bull. 2007; 30: 552-5
    CrossrefPubMedGoogle Scholar
  • 22 Saitoh H, Kobayashi M, Oda M, Nakasato K, Kobayashi M, Tadano K. Characterization of intestinal absorption and enterohepatic circulation of mycophenolic Acid and its 7-0-glucuronide in rats. Drug Metab Pharmacokinet. 2006; 21: 406-13
    CrossrefPubMedGoogle Scholar
  • 23 Chung HJ, Lee MG. Pharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos. 2006; 27: 345-51
    CrossrefPubMedGoogle Scholar
  • 24 Aiba T, Horiuchi M, Makita T, Komori Y, Kawasaki H, Kurosaki Y. Peritoneal dialysis alters tolbutamide pharmacokinetics in rats with experimental acute renal failure. Drug Metab Pharmacokinet. 2006; 21 (4) 291-6
    CrossrefPubMedGoogle Scholar
  • 25 Bae SK, Kwon JW, Kim WB, Lee I, Lee MG. Effects of acute renal failure on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. Biopharm Drug Dispos. 2006; 27: 29-37
    CrossrefPubMedGoogle Scholar
  • 26 Mustafa S, Venkatesh P, Pasha K, Mullangi R, Srinivas NR. Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?. Xenobiotica. 2006; 36: 1239-58
    CrossrefPubMedGoogle Scholar
  • 27 Lee EJ, Kim EJ, Kim YG, Chung HC, Kim SH, Kim DH, Lees I, Kim SG, Lee MG. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of 2-(allylthio) pyrazine, a chemoprotective agent, in rats: the role of CYP3A23 induction. Res Commun Mol Pathol Pharmacol. 2004; 115–116: 111-21
    PubMedGoogle Scholar
  • 28 Yamaguchi H, Yano I, Saito H, Inui K. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004; 21: 330-8
    CrossrefPubMedGoogle Scholar
  • 29 Shim HJ, Kim YC, Kim EJ, Kim DG, Kwon JW, Kim WB, Lee MG. Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos. 2004; 25: 137-42
    CrossrefPubMedGoogle Scholar
  • 30 Bae SK, Lee SJ, Kim JW, Kim YH, Kim SG, Lee MG. Effects of acute renal failure on the pharmacokinetics of oltipraz in rats. J Pharm Sci. 2004; 93: 2353-63
    CrossrefPubMedGoogle Scholar
  • 31 Lee AK, Lee JH, Kwon JW, Kim WB, Kim SG, Kim SH, Lee MG. Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos. 2004; 25: 273-82
    CrossrefPubMedGoogle Scholar
  • 32 Ahn CY, Kim EJ, Lee J, Kwon JW, Kim WB, Kim SG, Lee MG. Effects of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. J Pharm Sci. 2003; 92: 1604-13
    CrossrefPubMedGoogle Scholar
  • 33 Chung W, Kim EJ, Lee I, Kim SG, Lee MG, Kim SH. Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. Life Sci. 2003; 73: 253-63
    CrossrefPubMedGoogle Scholar
  • 34 Moon YJ, Lee AK, Chung HC, Kim EJ, Kim SH, Lee DC, Lee I, Kim SG, Lee MG. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos. 2003; 31: 776-84
    CrossrefPubMedGoogle Scholar
  • 35 Lee AK, Kim EJ, Lee MG. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. Res Commun Mol Pathol Pharmacol. 2003; 113–114: 193-200
    PubMedGoogle Scholar
  • 36 Lili C, Shibita N, Yoshikawa Y, Takada K. Effect of glycerol-induced acute renal failure on the pharmacokinetics of lidocaine after transdermal application in rats. Biol Pharm Bull. 2003; 26: 1150-4
    CrossrefPubMedGoogle Scholar
  • 37 Lee EJ, Kim EJ, Kim YG, Chung HC, Kim SH, Kim DH, Lee I, Kim SG, Lee MG. Pharmacokinetic changes of intravenous 2-(allylthio) pyrazine, a chemoprotective agent, in rats with acute renal failure induced by uranyl nitrate. Res Commun Mol Pathol Pharmacol. 2002; 111: 225-36
    PubMedGoogle Scholar
  • 38 Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull. 2002; 25: 1077-83
    CrossrefPubMedGoogle Scholar
  • 39 Son IJ, Moon YJ, Lee MG, Sohn YT. Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure. Res Commun Mol Pathol Pharmacol. 2000; 108: 359-68
    PubMedGoogle Scholar
  • 40 Park KJ, Yoon WH, Kim SH, Shin WG, Lee MG. Pharmacokinetic and pharmacodynamic changes of azosemide after intravenous and oral administration of azosemide to uranyl nitrate-induced acute renal failure rats. Biopharm Drug Dispos. 1998; 19: 141-6
    CrossrefPubMedGoogle Scholar
  • 41 Kim HJ, Han KS, Chung YK, Chang MS, Lee MG. Pharmacokinetic changes of a new proton pump inhibitor, YJA-20379–8, after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. Res Commun Mol Pathol Pharmacol. 1998; 102: 43-56
    PubMedGoogle Scholar
  • 42 Kim SH, Shim HJ, Kim WB, Lee MG. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrob Agents Chemother. 1998; 42: 1217-21
    PubMedGoogle Scholar
  • 43 Park JM, Moon CH, Lee MG. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. Res Commun Mol Pathol Pharmacol. 1996; 93: 353-62
    PubMedGoogle Scholar
  • 44 Kim YG, Yoon EJ, Yoon WH, Shim HJ, Lee SD, Kim WB, Yang J, Lee MG. Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. Biopharm Drug Dispos. 1996; 17: 183-95
    CrossrefPubMedGoogle Scholar
  • 45 Lee HJ, Paik WH, Lee MG. Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to uranyl nitrate-induced acute renal failure rats. Res Commun Mol Pathol Pharmacol. 1996; 91: 195-204
    PubMedGoogle Scholar
  • 46 Lee YH, Lee MH, Shim CK. Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. Pharm Res. 1992; 9: 1599-606
    CrossrefPubMedGoogle Scholar
  • 47 Arimori K, Nakano M. Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure. J Pharmacobiodyn. 1988; 11: 504-11
    CrossrefPubMedGoogle Scholar
  • 48 Kamiya A, Hayashi Y, Kikkoji T, Huang Y, Inui K, Hori R. Increased diuretic response to furosemide in rats with glycerol-induced acute renal failure. J Pharmacobiodyn. 1988; 11: 541-8
    CrossrefPubMedGoogle Scholar
  • 49 Yasuhara M, Katayama H, Fujiwara J, Okumura K, Hori R. Influence of acute renal failure on pharmacokinetics of phenolsulfonphthalein in rats: a comparative study in vivo and in the simultaneous perfusion system of liver and kidney. J Pharmacobiodyn. 1985; 8: 377-84
    CrossrefPubMedGoogle Scholar
  • 50 Yates MS, Bowmer CJ, Emmerson J. The plasma clearance of indocyanine green in rats with acute renal failure: effect of dose and route of administration. Biochem Pharmacol. 1983; 32: 3109-14
    CrossrefPubMedGoogle Scholar
  • 51 Shibata N, Inoue Y, Fukumoto K, Nishimura A, Fukushima K, Yoshikawa Y, Spiteller G, Takada K. Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure. Biol Pharm Bull. 2004; 27: 384-91
    CrossrefPubMedGoogle Scholar
  • 52 Shibata N, Morimoto J, Hoshino N, Minouchi T, Yamaji A. Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. Ren Fail. 2000; 22: 181-94
    CrossrefPubMedGoogle Scholar
  • 53 Igarashi T, Yano I, Saito H, Inui K. Decreased cyclosporin A concentrations in the absorption phase using microemulsion preconcentrate formulation in rats with cisplatin-induced acute renal failure. Biol Pharm Bull. 2003; 6: 1591-5
    PubMedGoogle Scholar
  • 54 Lee YH, Park KH, Ku YS. Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. Int J Pharm. 2000; 194: 221-7
    CrossrefPubMedGoogle Scholar
  • 55 Shibata N, Ohmae T, Hoshino N, Minouchi T, Yamaji A. Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. J Pharm Pharmacol. 1999; 51: 397-404
    CrossrefPubMedGoogle Scholar
  • 56 Okabe H, Mizukami A, Taguchi M, Aiba T, Yasuhara M, Hashimoto Y. The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction. J Pharm Pharmacol. 2003; 55: 479-86
    CrossrefPubMedGoogle Scholar
  • 57 Hori R, Okumura K, Yasuhara M, Katayama H. Reduced hepatic uptake of propranolol in rats with acute renal failure. Biochem Pharmacol. 1985; 34: 2679-83
    CrossrefPubMedGoogle Scholar
  • 58 Katayama H, Fujiwara J, Yasuhara M, Okumura K, Hori R. Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure. J Pharmacobiodyn. 1984; 7: 536-44
    CrossrefPubMedGoogle Scholar
  • 59 Barthelmebs M, Wiernsperger N, Krieger JP, Rapin JR, Radziuk J, Grima M, Imbs JI. Mild acute renal failure potentiates metformin accumulation in the diabetic rat kidney without further impairment of renal function. Diabetes Metab. 2003; 29: 163-70
    CrossrefPubMedGoogle Scholar
  • 60 He YL, Kitada N, Yasuhara M, Hori R. Quantitative estimation of renal clearance of N-acetylprocainamide in rats with various experimental acute renal failure. Eur J Pharm Sci. 2001; 13: 303-8
    CrossrefPubMedGoogle Scholar
  • 61 Clark LC, Farghaly H, Saba SR, Vesely DL. Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days. Am J Physiol Heart Circ Physiol. 2000; 278: H1555-64
    PubMedGoogle Scholar
  • 62 Lee YH, Ku YS. Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. Res Commun Mol Pathol Pharmacol. 1998; 102: 251-64
    PubMedGoogle Scholar
  • 63 Lee YH, Ku YS. Effects of cyclosporin on the pharmacokinetics of propranolol after intravenous and oral administration to control rats and to rats with uranyl nitrate-induced acute renal failure. J Pharm Pharmacol. 1999; 51: 1149-54
    CrossrefPubMedGoogle Scholar
  • 64 Ruschitzka F, Shaw S, Gygi D, Noll G, Barton M, Lüscher TF. Endothelial dysfunction in acute renal failure: role of circulating and tissue endothelin-1. J Am Soc Nephrol. 1999; 10: 953-62
    PubMedGoogle Scholar
  • 65 Londono I, Marshansky V, Bourgoin S, Vinay P, Bendayan M. Expression and distribution of adenosine diphosphate-ribosylation factors in the rat kidney. Kidney Int. 1999; 55: 1407-16
    CrossrefPubMedGoogle Scholar
  • 66 Shibata N, Shimakawa H, Minouchi T, Yamaji A. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states. Biol Pharm Bull. 1993; 16: 1130-5
    CrossrefPubMedGoogle Scholar
  • 67 Kikkoji T, Kamiya A, Inui K, Hori R. Urinary excretion and diuretic action of furosemide in rats: increased response to the urinary excretion rate of furosemide in rats with acute renal failure. Pharm Res. 1988; 5: 699-703
    CrossrefPubMedGoogle Scholar
  • 68 Bowmer CJ, Emmerson J, Yates MS. Delayed biliary excretion of indocyanine green in rats with glycerol-induced acute renal failure. Biochem Pharmacol. 1983; 32: 1641-2
    CrossrefPubMedGoogle Scholar
  • 69 Chander V, Singh D, Chopra K. Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine. Pharmacology. 2003; 67: 41-8
    CrossrefPubMedGoogle Scholar
  • 70 de Rougemont D, Oeschger A, Konrad L, Thiel G, Torhorst J, Wenk W, Wunderlich P, Brunner FP. Gentamicin-induced acute renal failure in the rat: effect of dehydration, DOCA-saline and furosemide. Nephron. 1981; 29: 176-84
    CrossrefPubMedGoogle Scholar
  • 71 Ozyurt H, Yildirim Z, Kotuk M, Yilmaz HR, Yagmurca M, Iraz M, Sogut S, Gergerlioglu S. Cisplatin-induced acute renal failure is ameliorated by erdosteine in a dose-dependent manner. J Appl Toxicol. 2004; 24: 269-75
    CrossrefPubMedGoogle Scholar
  • 72 Jones TW, Chopra S, Kaufman JS, Flamenbaum W, Trump BF. Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations. Lab Invest. 1985; 52: 363-73
    PubMedGoogle Scholar
  • 73 Gupta E, Safa AR, Wang X, Ratain MJ. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporine A. Cancer Res. 1996; 56: 1309-14
    PubMedGoogle Scholar
  • 74 Churchill PC, Bidani AK. Hypothesis: Adensoine mediates hemodynamic changes in renal failure. Medical Hypoth. 1982; 8: 275-85
    PubMedGoogle Scholar
  • 75 Kayouka M, Houze P, Debray M, Baud FJ. Acute renal failure enhances the antidotal activity of pralidoxime towards paraoxon-induced respiratory toxicity. Toxicol Lett. 2009; 189: 48-56
    CrossrefPubMedGoogle Scholar
  • 76 Kayouka M, Houze P, Risede P, Debray M, Baud FJ. Acute renal failure alters the kinetics of pralidoxime in rats. Toxicol Lett. 2009; 184: 61-6
    CrossrefPubMedGoogle Scholar